1. Home
  2. IBRX vs CIVI Comparison

IBRX vs CIVI Comparison

Compare IBRX & CIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$6.23

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Civitas Resources Inc.

CIVI

Civitas Resources Inc.

HOLD

Current Price

$27.97

Market Cap

2.6B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
CIVI
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
IBRX
CIVI
Price
$6.23
$27.97
Analyst Decision
Strong Buy
Hold
Analyst Count
5
13
Target Price
$11.80
$40.20
AVG Volume (30 Days)
46.1M
1.2M
Earning Date
03-02-2026
02-23-2026
Dividend Yield
N/A
7.39%
EPS Growth
N/A
N/A
EPS
N/A
6.86
Revenue
$82,555,000.00
$4,711,808,000.00
Revenue This Year
$680.06
N/A
Revenue Next Year
$90.18
N/A
P/E Ratio
N/A
$3.94
Revenue Growth
1025.95
N/A
52 Week Low
$1.83
$22.79
52 Week High
$8.28
$53.02

Technical Indicators

Market Signals
Indicator
IBRX
CIVI
Relative Strength Index (RSI) 75.41 55.91
Support Level $5.71 $25.83
Resistance Level $8.28 $28.41
Average True Range (ATR) 0.67 1.12
MACD 0.42 0.21
Stochastic Oscillator 67.10 84.18

Price Performance

Historical Comparison
IBRX
CIVI

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About CIVI Civitas Resources Inc.

Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.

Share on Social Networks: